The Food and Drug Administration (FDA) has approved Xtoro (finafloxacin otic suspension; Alcon) for the treatment of acute otitis externa (also known as swimmer's ear) caused by Pseudomonas aeruginosa and Staphylococcus aureus.
Some people with cochlear implants experience pain, discomfort, and problems with the implant's internal magnet when they undergo magnetic resonance imaging (MRI).
Nearly one million patient visits are made to doctors offices, outpatient clinics, and emergency departments for keratitis each year in the United States, with contact lens wear as the single largest risk factor for microbial keratitis.
Featured courses from mycme
An understanding of the growing problem of allergic disease, how AD is the entryway into ...
This module reviews all topics on the NCCPA examination blueprint relating to Pulmonology, Ophthalmology, and ...
This activity covers the diagnosis and management of acute otitis externa and proposes a grading ...
- First-in-Class Drug for Advanced Ovarian Cancer Approved
- Too Late to Get the Influenza Vaccine? Not So, Says CDC
- Vision Loss Risk Cut in Half with Prostaglandin Analogue Eye Drops for Glaucoma
- Evidence's Role in OTC Decision Making by Pharmacists
- Report: States Ill-Prepared for Ebola, Other Infectious Outbreaks